Cite
HARVARD Citation
Glasspool, R. et al. (n.d.). 596 A randomised phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. (NICCC/ENGOT-OV36). International journal of gynecological cancer. pp. A127-A128. [Online].